AMANTA HEALTHCARE LTD.

August 29, 2025

SMC Ranking

★½☆☆☆ (1.5/5)

Issue Highlights

Industry	Healthcare
Fresh Issue (Shares)	10,000,000
Net Offer to the Public	**10,000,000**
Issue Size (Rs. Cr.)	120-126
Price Band (Rs.)	120-126
Offer Date	1-Sep-25
Close Date	3-Sep-25
Face Value	10
Lot Size	119

Issue Composition

	In shares
Total Issue for Sale	10,000,000
QIB	5,000,000
NIB	1,500,000
Retail	3,500,000

Shareholding Pattern (%)

Particulars	Pre-issue	Post -issue
Promoters & promoters group	85.60%	63.56%
QIB	14.40%	23.57%
NIB	0.00%	3.86%
Retail	0.00%	9.01%
Total	**100.00%**	**100.00%**

*calculated on the upper price band

Objects of the Issue

The Company Amanta Healthcare IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

1. Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat
2. Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat
3. General corporate purposes

Book Running Lead Manager

- Beeline Capital Advisors Private Limited

Name of the registrar

- MUFG Intime India Private Limited (formerly Link intime India Private Limited)

About the company

Amanta Healthcare Limited, incorporated in December 1994, is a pharmaceutical company engaged in the development, manufacturing, and marketing of sterile liquid products, primarily parenteral formulations packaged using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company also manufactures medical devices, offering a wide portfolio that includes IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions, first-aid products, and eye lubricants. Its operations are structured across three business units—national sales, international sales, and product partnering with domestic and global pharmaceutical companies. With a portfolio of over 45 generic products marketed under its own brands in India through 320 distributors and stockists, Amanta has established a strong domestic presence while also exporting to Africa, Latin America, the UK, and other markets. The company's products are registered in 19 countries, and in FY2025, its branded exports reached 21 countries. As of March 31, 2025, Amanta employed 1,718 people across its formulation, development, and quality laboratories.

Strength

Well-established manufacturer with a diverse product portfolio: Incorporated in 1994, Amanta Healthcare Limited has built a strong presence as a manufacturer of pharmaceutical formulations with a portfolio of 47 products across six therapeutic categories—fluid therapy, formulations, diluents, ophthalmic, respiratory care, and irrigation solutions. The company offers a broad range of closure systems and container fill-volumes ranging from 2ml to 1000ml, ensuring flexibility and scale. With product registrations in 120 international jurisdictions, Amanta benefits from business consistency and long-term sustainability.

Robust manufacturing capabilities: Amanta Healthcare emphasizes quality as a cornerstone of its operations, reflected in its consistent regulatory compliance and successful inspections. Its advanced manufacturing facility, spread over 66,852 square meters in Gujarat, India, houses two manufacturing blocks, utility blocks, centralized QA/QC departments, and administrative offices. The company operates four Large Volume Parenterals (LVP) lines and three Small Volume Parenterals (SVP) lines, enabling production across multiple fill volumes and closure systems. Accredited with ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018, and WHO-GMP certifications, the facility provides scalability from laboratory-scale research to full-scale commercial production, strengthening the company's ability to adapt to evolving market demands.

Extensive domestic and global distribution network: Amanta Healthcare has established a wide-reaching sales and distribution network, supported by over 320 distributors and stockists across India and a dedicated sales team of nearly 100 professionals. Its core distribution model focuses on supplying products through these partners to hospitals and nursing homes. To improve operational efficiency and demand responsiveness, the company has integrated its IT systems with distribution operations through its Pharma Cloud platform, which streamlines sales transactions, demand planning, and forecasting. Additionally, the use of sales force automation tools enhances the productivity and effectiveness of its sales team.

Strong leadership and skilled workforce: Amanta Healthcare is guided by an experienced leadership team, spearheaded by Bhavesh Patel, Promoter, Chairman, and

Managing Director, with nearly three decades of industry expertise. The senior management team brings diverse academic and professional backgrounds in accounts, science, and pharmacy, providing a well-rounded strategic foundation. As of March 31, 2025, the company employed more than 506 professionals across various functions. This skilled workforce not only drives innovation and operational excellence but also supports expansion into new products and geographies. Amanta's reputation as a leading pharmaceutical formulations manufacturer helps attract and retain top scientific talent, ensuring sustained differentiation and competitiveness in the market.

Strategy

Expansion of manufacturing capacities: Amanta Healthcare Limited operates four Large Volume Parenterals (LVP) manufacturing lines, comprising two conventional single-port lines using ABFS technology and two SteriPort product lines using ISBM technology. In addition, it runs three Small Volume Parenterals (SVP) lines, including two ABFS lines and one conventional three-piece container filling line. The company's three primary product segments—Large Volume Parenteral (Nipple Head), SteriPort (Two Ports), and Small Volume Parenteral—offer varied margin profiles ranging from 20% to over 60%. To address supply shortages and enhance product availability, Amanta plans to expand its manufacturing capacity across these segments.

National sales business: The company's national sales operations cover both branded and generic products. Its branded portfolio, marketed under the name SteriPort, includes large-volume parenteral products that are promoted and distributed across India. The generics segment focuses on developing, manufacturing, and distributing cost-effective formulations for the domestic and international markets. Amanta's branded generics strategy is designed to meet India's growing demand for affordable, high-quality medicines and spans multiple dosage forms, including injectables, ophthalmic solutions, and irrigation products.

Expansion of national sales network: Amanta Healthcare is focused on strengthening its domestic presence by expanding its SteriPort brand for large-volume products. The company intends to grow its nationwide network beyond its current 320 distributors and stockists through an enhanced sales and marketing team dedicated to building stronger relationships and supporting new product launches. To drive growth, Amanta also plans to introduce target-based incentive programs for distributors while actively engaging with new retailers to broaden its reach.

Expanding wallet share and customer base: Amanta Healthcare is committed to deepening engagement with existing customers while attracting new clients by leveraging its formulation and development expertise and large-scale manufacturing capacity. The company aims to expand its wallet share through new product introductions and complex dosage forms, supported by long-standing customer relationships and a track record of reliable delivery. Its sales and marketing team of 96 professionals in India, along with a five-member international team, plays a pivotal role in driving growth. The formulation and development department has helped expand the commercialized product portfolio from 41 products in FY2023 to 47 in FY2025, strengthening Amanta's ability to retain customers and win new business.

Risk Factor

- Amanta Healthcare operates from a single facility in Gujarat; any disruption due to power outages, disasters, or machinery breakdowns could significantly impact operations and financials.
- As a governance measure, Amanta has offered exits to certain past shareholders, having earlier issued equity shares to more than 49 investors.
- Being labour-intensive, operations face risks from strikes, wage hikes, or challenges in hiring at viable costs, which may affect performance and profitability.
- The company's manufacturing license has faced suspension in the past; future suspensions could disrupt operations and adversely affect financial results.

Peer Comparison

Co_Name	Total Income	PAT	EPS	P/E	P/BV	BV	FV	Price	Mcap
Denis Chem Lab	173.30	8.08	6.11	15.39	1.53	61.33	10	94.03	130.48
AMANTA HEALTHCARE LTD	274.71	10.50	2.70	46.59	2.20	57.27	10	126.00	489.25

***Peer companies financials are TTM based**
****AMANTA HEALTHCARE LTD based on Actual FY25**

Valuation

Considering the P/E valuation, on the upper end of the price band of Rs126, the stock is priced at pre issue P/E of 34.59x on FY25 EPS of Rs 3.64. Post issue, the stock is priced at a P/E of 46.59x on its EPS of Rs. 2.70. Looking at the P/B ratio at Rs.126 pre issue, book value of Rs.33.43 of P/Bvx 3.77x. Post issue, book value of Rs.57.27 of P/Bvx 2.20x.

Considering the P/E valuation, on the lower end of the price band of Rs.120, the stock is priced at pre issue P/E of 32.95x on FY25 EPS of Rs. 3.64. Post issue, the stock is priced at a P/E of 44.37x on its EPS of Rs. 2.70. Looking at the P/B ratio at Rs. 126 pre issue, book value of Rs. 33.43 of P/Bvx 3.59x. Post issue, book value of Rs.57.27 of P/Bvx 2.10x.

Industry Outlook

As per CRISIL Report, as per the International Monetary Fund's (IMF) April 2025 update, global gross domestic product (GDP) growth witnessed a growth of 3.3% in 2024 as signs of stabilization emerged- inflation came down from multidecade highs, followed a gradual as well as labor markets normalized, with unemployment and vacancy rates returning to pre pandemic levels, IV fluid market consisting of key products like normal saline, dextrose, lactate ringer and electrolytes have seen traction in recent years owing to growth of overall healthcare system in India. Indian IV fluids market is estimated to be valued at ~Rs 45-47 billion as of fiscal 2024, compared to ~Rs 29 billion in fiscal 2019. This growth was supported by multiple factors including rising population, increasing prevalence of chronic diseases, and growing demand for IV fluids in medical treatments due to fast acting way. Going ahead with growth of overall healthcare delivery market in India and the factors outlined above the industry is estimated to register a CAGR of ~9-11% between fiscals 2024- 2029 and reach Rs ~70-80 billion by fiscal 2029 owning to sustained demand from end use segments like hospitals and clinics. The healthcare budget has seen increases on-year. Between FY11 and FY25, the budget for the MoHFW clocked a CAGR of ~10%. In recent years, the utilisation rate has been 100% or above, as has been the case since FY16. This, too, is a strong growth driver for the industry and particularly the PPP initiative from government so as to achieve the government's goal of providing healthcare services to all.

Outlook

Amanta Healthcare Limited, with its strong manufacturing base, diversified product portfolio, and expanding domestic and international presence, is well-positioned to capture growth opportunities in the pharmaceutical sector. Its focus on branded generics, capacity expansion, and a widening sales network supports long-term sustainability. However, dependence on a single-site facility, regulatory risks, and labour-intensive operations pose potential challenges. With continuous innovation, strong customer relationships, and compliance-driven practices, the company aims to enhance profitability while mitigating risks, ensuring steady business growth and resilience.

An Indicative timetable in respect of the Issue is set out below:

EVENT	INDICATIVE DATE (On or about)
BID/ISSUE OPENS ON	01-September-25
BID/ISSUE CLOSES ON	03-September-25
Finalisation of Basis of Allotment with the Designated Stock Exchange	04-September-25
Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account	08-September-25
Credit of Equity Shares to Demat Accounts of Allottees	08-September-25
Commencement of trading of the Equity Shares on the Stock Exchanges	09-September-25

Annexure

Consolidated Financials

Profit & Loss

Rs. in Cr.

Particulars	Period ended 31-Mar-25 (12 Months)	Period ended 31-Mar-24 (12 Months)	Period ended 31-Mar-23 (12 Months)
Revenue from operations	274.71	280.34	259.13
Total expenditure	215.04	222.85	206.39
Operating Profit	**59.67**	**57.49**	**52.74**
OPM%	2.17	2.05	2.04
Other Income	1.39	1.27	3.57
Total Net Income	**61.05**	**58.76**	**56.31**
Interest	27.95	33.64	35.27
PBDT	**33.11**	**25.12**	**21.04**
Depreciation	18.40	19.73	18.35
PBT	**14.71**	**5.39**	**2.69**
Tax	4.21	1.76	4.80
PAT	**10.50**	**3.63**	**-2.11**

Balance sheet is on next page

Balance Sheet

Rs. in Cr.

Particulars	As on 31-Mar-25	As on 31-Mar-24	As on 31-Mar-23
Non-current assets			
Financial liabilities			
Property, Plant and Equipment	207.68	222.72	228.79
Capital work in progress	6.55	0.00	0.00
Right-of-use assets	8.55	5.41	8.80
Intangible Assets	0.92	0.02	0.09
Financial Assets			
Loans	0.21	0.12	0.09
Investments	7.72	3.72	3.47
Other Financial Assets	0.92	1.03	1.58
Non current tax assets (net)	0.00	0.00	0.00
Other non-current assets	11.31	1.21	0.24
Total non-current assets	**243.84**	**234.23**	**243.06**
Current asset			
Inventories	72.98	59.45	68.92
Financial Assets			
Trade receivables	50.08	48.17	53.58
Cash and cash equivalents	0.22	1.54	0.11
Bank balances other than cash and cash equivalents	3.26	2.56	3.76
Loans	0.45	0.19	0.16
Other financial Assets	0.02	0.00	0.00
Other current assets	10.91	5.99	4.48
Total current assets	**137.92**	**117.89**	**131.01**
Total Assets	**381.76**	**352.12**	**374.06**
Non-current liabilities			
Financial Liabilities			
Borrowings	132.36	149.03	175.55
Lease Liabilities	7.74	5.43	6.51
Deferred tax liabilities (net)	30.19	29.71	31.98
Total Non- Current liabilities	**170.29**	**184.17**	**214.04**
Current liabilities			
Financial Liabilities			
Borrowings	62.64	56.20	40.11
Lease Liabilities	1.20	0.43	2.55
Trades Payable - total outstanding dues of micro enterprises and small enterprises	2.22	0.44	0.77
Trades Payable - total outstanding dues of creditors other than micro enterprises and small enterprises	28.28	24.36	35.44
Other financial liabilities	3.50	2.69	2.98
Contract liabilities	6.21	8.42	5.46
Other current liabilities	1.91	1.45	1.34
Provisions	8.01	6.47	5.61
Current Tax Liabilities (net)	1.12	1.19	2.87
Total Current liabilities	**115.08**	**101.66**	**97.13**
Total	**285.37**	**285.83**	**311.18**
Net worth represented by:			
Equity Share Capital	28.83	26.83	26.83
Other equity	67.56	39.46	36.05
Net Worth	**96.39**	**66.29**	**62.88**

RANKING METHODOLOGY

WEAK	★
NEUTRAL	★★
FAIR	★★★
GOOD	★★★★
EXCELLENT	★★★★★

E-mail: researchfeedback@smcindiaonline.com

Corporate Office:
11/6B, Shanti Chamber,
Pusa Road, New Delhi - 110005
Tel: +91-11-30111000
www.smcindiaonline.com

Mumbai Office:
Lotus Corporate Park , A Wing 401 / 402 ,
4th Floor ,Graham Firth Steel Compound,
Off Western Express Highway, Jay Coach Signal,
Goreagon (East) Mumbai - 400063
Tel: 91-22-67341600, Fax: 91-22-28805606

Kolkata Office:
18, Rabindra Sarani,
Poddar Court,Gate No.- 4, 5th Floor, Kolkata-700001
Tel: 91-33-39847000, Fax: 91-33-39847004

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The securities quoted are for illustration only and are not recommendatory. SMC is a SEBI registered Research Analyst having registration number INH100001849. CIN : L74899DL1994PLC063609.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.

Disclaimer: This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s)in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance if this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.